



PRESS RELEASE

For Immediate Release

Contact: info@globalcancertechnology.com

GLOBAL CANCER TECHNOLOGY INITIATES PRECLINICAL STUDIES FOR DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) AT BROWN UNIVERSITY LEGORRETA CANCER CENTER

RESULTS IN EARLY STUDIES INDICATE A POTENTIAL SYNERGY BETWEEN GCT'S PI3K INHIBITOR DRUG GCT007 AND ONC201 IN INITIAL STUDY RESULTS

San Diego, CA, March 15, 2023 – Global Cancer Technology, Inc. announced today that pre-clinical studies testing the use of GCT-007 in DIPG human cell lines at Brown University's Legorreta Cancer Center have been initiated. Preliminary data indicate a potential synergy between GCT007 and ONC201 in several of the DIPG cell lines. .

"We are excited to be working with Dr. Wafik S. El-Deiry, who is the Director of the Legorreta Cancer Center and Associate Dean, Oncologic Sciences-Warren Alpert Medical School of Brown University and his team of investigators," said M. Karen Newell Rogers, PhD-Chief Scientific consultant for Global Cancer Technology and a Professor and Immunologist at Texas A&M University.

"The Legorreta Cancer Center is looking forward to additional exploration of ONC201 synergy using GCT-007 in additional DIPG cell lines," said Dr. El-Deiry. "We are encouraged by the pre-clinical study results achieved to date and want to expand additional validation that will include work aimed at understanding the mechanism of the synergy between the two drugs," Dr. El-Deiry further added.

"It is an honor to be collaborating and associated with such a prestigious institution as the Brown University Legorreta Cancer Center," said John Clark, the CEO of Global Cancer Technology. Mr. Clark further added, "Dr. El-Deiry is directing a well-known and world class research facility that will greatly assist in our progress and goal of entering a Phase I clinical trial for DIPG with our GCT-007 drug."

Global Cancer Technology is a non-revenue biopharma company that is currently raising investment capital to enter a glioblastoma Phase 1 clinical trial.

Globalcancertechnology.com

Statements in this news release may contain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1993 and Section 21E of the Securities and Exchange Act of 1934. Such statements may involve various risks and uncertainties, some of which may be discussed in the Company's most recent shareholder letter. There is no assurance any new products can be cleared for sale by the FDA or successfully commercialized.